Related Experiment Video
Updated: Jun 13, 2026

Cardiac Stress Test Induced by Dobutamine and Monitored by Cardiac Catheterization in Mice
Published on: February 10, 2013
Left ventricular hypertrophy influences cardiac prognosis in patients undergoing dobutamine cardiac stress testing
Charaslak Charoenpanichkit1, Timothy M Morgan, Craig A Hamilton
1Departments of Internal Medicine Cardiology Section, Public Health Sciences, Biomedical Engineering, and Radiology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1045, USA.
Insights
Left ventricular hypertrophy (LVH) predicts myocardial infarction (MI) and cardiac death in patients undergoing dobutamine stress tests. Reporting LVH is crucial, especially for patients without inducible ischemia, to refine cardiac risk assessment.
Area of Science:
- Cardiology
- Diagnostic Imaging
- Cardiac Physiology
Background:
- Chest pain is a common symptom requiring accurate diagnosis.
- Left ventricular hypertrophy (LVH) is a structural heart change that may impact cardiac prognosis.
- Dobutamine stress testing is used to evaluate patients with suspected or known coronary artery disease.
Purpose of the Study:
- To assess the predictive value of dobutamine stress test findings for myocardial infarction (MI) and cardiac death.
- To determine if left ventricular hypertrophy (LVH) independently predicts adverse cardiac events.
- To evaluate the utility of dobutamine stress testing in patients with chest pain and LVH.
Main Methods:
- 353 participants with chest pain underwent dobutamine cardiovascular magnetic resonance (CMR) stress testing.
- Participants were followed for a mean of 6 years to track MI or cardiac death.
- Left ventricular (LV) mass was measured, with LVH defined by sex-specific mass index criteria.
Main Results:
- LVH was present in 17-18% of participants.
- 20% of participants experienced MI or cardiac death during follow-up.
- LVH was an independent predictor of MI and cardiac death (HR=1.99, P=0.02) in multivariable analysis, even in the presence of ischemia.
Conclusions:
- Left ventricular hypertrophy (LVH) is a significant predictor of future MI and cardiac death.
- LVH should be reported in dobutamine stress test results, particularly for patients without inducible ischemia.
- Identifying LVH can help refine risk stratification and patient management.
Background:
This study was performed to determine the utility of dobutamine stress test results for predicting myocardial infarction (MI) and cardiac death in patients with chest pain and left ventricular hypertrophy (LVH).
Methods And Results:
Three hundred fifty-three participants with a mean+/-SD age of 64+/-12 years (54%men) underwent dobutamine cardiovascular magnetic resonance stress testing and then were followed up for 6+/-2 years (mean+/-SD; range, 0.5-11.5) to assess the post-dobutamine cardiovascular magnetic resonance stress test occurrence of MI or cardiac death. LV mass and the presence or absence of ischemia were determined; LVH was defined as an LV mass index >96 g/m(2) in men and >77 g/m(2) in women. LVH was present in 62 participants (18% of the men and 17% of the women, P=0.90). Seventy-one (20%) participants experienced an MI or cardiac death during follow-up. The MI and cardiac death rate was more frequent in those with versus without LVH (32% vs 17%, P=0.009). In multivariable analysis that accounted for the presence of preexisting coronary artery disease, hypertension, diabetes, stress-induced ischemia, and reduced LV ejection fraction, LVH was an independent predictor of MI and cardiac death (hazard ratio=1.99; 95% CI, 1.13-3.50; P=0.02).
Conclusions:
LVH is predictive of future MI and cardiac death in patients with or without inducible ischemia during dobutamine cardiac stress testing. As a result, LVH should be reported in those referred for dobutamine cardiac stress tests, particularly in those without inducible ischemia, in whom one would otherwise assume a favorable cardiac prognosis.
Related Concept Videos
Heart Failure II: Pathophysiology
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Mitral Stenosis I: Introduction
Mitral Regurgitation I: Introduction
Cardiomyopathy V: Interprofessional Care
